[15] In both trials, after 72 weeks of treatment, participants who received tirzepatide at all three dose levels experienced a statistically significant reduction in body weight compared to those who received placebo, and greater proportions of participants who received tirzepatide achieved at least 5% weight reduction compared to placebo
In SELECT, the 2.4 mg dose produced a 20% reduction in major cardiovascular events
Until recently, drugs that directly target renal tubular injury in patients with DKD have been limited
However, this is early research, and more studies are needed to confirm these findings in larger and more diverse groups
For patients with diabetes and MASLD, SGLT2 inhibitors may offer metabolic and cardiovascular benefits while potentially improving liver health
Getting GLP-1 the Natural Way: How to Do It and How It Helps October 17, 2025 Categories: Weight Loss, Diabetes Today, people who deal with being overweight or obese and have diabetes have a new way to lose weight and gain control over their condition
